Epigenetic research reveals a potential treatment for CRC and other solid tumors

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.

July 11, 2025

Vol.51 No.27

In Brief

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Nicholas M. Jaidar was named senior administrator for oncology at the Department of Oncology at the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital.

June 27, 2025

Vol.51 No.25

Clinical Roundup

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.

June 20, 2025

Vol.51 No.24

Clinical Roundup

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

Researchers at the University of Chicago Medicine Comprehensive Cancer Center have discovered that high doses of radiation cause growth in existing metastatic tumors that weren’t directly treated with radiation.

May 16, 2025

Vol.51 No.19

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

April 18, 2025

Vol.51 No.15

By Jacquelyn Cobb

Epigenetic research reveals a potential treatment for CRC and other solid tumors

YOU MAY BE INTERESTED IN

An overlooked immune cell population may offer new direction for cell and gene therapy

“Power surges” on cancer cell membranes may fuel progression of disease, Johns Hopkins study finds

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

UChicago study reveals high doses of radiation can cause growth in existing metastatic tumors

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Renew today!

Subscriber content

Never miss an issue!

Login